Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.67 |
| ▸ | CTSK | P43235 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1951088 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL3825684 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL3205842 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL627379 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL2159319 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL16710011 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL12189206 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| SCHEMBL629960 | 1.00 | CTSS (0.67) | CTSSCTSKALDH1A1KMT2APSENEN | |
| Water SCHEMBL5203435 | 0.98 | CTSK (0.69) | CTSSCTSKALDH1A1KMT2APSENEN | |
| Water SCHEMBL10884567 | 0.98 | CTSK (0.69) | CTSSCTSKALDH1A1KMT2APSENEN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478627-A | Allylation monophosphine ligand and preparation method thereof | 湖北大学 | 2022-05-13 | — | — | CN | claimed |
| CN-109851635-B | Novel alkylated monophosphine ligand and simple preparation method thereof | 湖北大学 | 2021-03-16 | — | — | CN | claimed |
| CN-112250709-A | Synthesis method of ortho-aryl substituted tertiary phosphine compound | 湖北大学 | 2021-01-22 | — | — | CN | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| CN-111592567-A | Synthesis method of bidentate phosphine ene ligand | 湖北大学 | 2020-08-28 | — | — | CN | claimed |
| EP-3231798-B1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | claimed |
| US-10000520-B2 | B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof | ChromaDex Inc. (US) | 2018-06-19 | — | — | US | claimed |
| US-20170267709-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OFNICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | ChromaDex Inc. (US) | 2017-09-21 | — | — | US | claimed |
| US-9556177-B2 | Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | claimed |
| CN-101274958-A | Bioactive peptide, preparation thereof and application thereof | OCEAN UNIV CHINA (CN) | 2008-10-01 | — | — | CN | claimed |
| US-7265140-B2 | Acyloxymethylcarbamate prodrugs of oxazolidinones | PFIZER INC (US) | 2007-09-04 | — | — | US | claimed |
| EP-1668005-B1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1668005-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | Pharmacia & Upjohn Company LLC (US) | 2006-06-14 | — | — | EP | claimed |
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | PHARMACIA & UPJOHN COMPANY LLC | 2005-12-01 | — | — | US | claimed |
| WO-2005028473-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-03-31 | — | — | WO | claimed |
| US-5757408-A | PRINTING IMAGE ON SUBSTRATE COATED WITH AMINO-ACID DERIVATIVE ADDITIVE; QUICK DRYING OF INK, OPTICAL DENSITY, NONCURLING | XEROX CORPORATION (US) | 1998-05-26 | — | — | US | claimed |
| US-5683793-A | Ink jet transparencies | XEROX CORPORATION (US) | 1997-11-04 | — | — | US | claimed |
| US-5589277-A | INK JET PRINTING, AQUEOUS INKS, FAST DRYING | XEROX CORPORATION (US) | 1996-12-31 | — | — | US | claimed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| US-12625431-B2 | EUV resist underlayer film-forming composition | NISSAN CHEMICAL CORPORATION (JP) | 2026-05-12 | — | — | US | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20250059171-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4444711-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-10-16 | — | — | EP | disclosed |
| US-20240217930-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| CN-117858867-A | SARS-COV-2 MPRO inhibitor compounds | 赫普泰雅治疗有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117143114-B | BRD4 and Src double-target inhibitor and preparation method and application thereof | 深圳大学 | 2024-02-20 | — | — | CN | disclosed |
| EP-4313305-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117417272-A | Preparation method of Boc-D-isoleucine | 上海海皋科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117304129-A | Azaalkanone derivative or pharmaceutically acceptable salt thereof, preparation method and application thereof, and pharmaceutical composition | 中国医学科学院医药生物技术研究所 | 2023-12-29 | — | — | CN | disclosed |
| WO-2023239166-A1 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 대웅제약 | 2023-12-14 | — | — | WO | disclosed |
| CN-117143114-A | BRD4 and Src double-target inhibitor and preparation method and application thereof | 深圳大学 | 2023-12-01 | — | — | CN | disclosed |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-14 | — | — | US | disclosed |
| CN-116410143-A | Polysubstituted uracil derivative, preparation method and application thereof | 杭州奥默医药股份有限公司 | 2023-07-11 | — | — | CN | disclosed |
| WO-2023104882-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-06-15 | — | — | WO | disclosed |
| US-20230098881-A1 | EUV RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4108666-A1 | MULTI-TARGET TYROSINE KINASE INHIBITOR | Shenzhen Neptunus Pharmaceutical Research Institute Co., Ltd. (CN) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022208113-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-10-06 | — | — | WO | disclosed |
| CN-114478627-A | Allylation monophosphine ligand and preparation method thereof | 湖北大学 | 2022-05-13 | — | — | CN | disclosed |
| US-11274124-B2 | Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith | WILLIAM MARSH RICE UNIVERSITY (US) | 2022-03-15 | — | — | US | disclosed |
| US-11192878-B2 | Piperidine-2,6-dione derivative and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2021-12-07 | — | — | US | disclosed |
| EP-3898843-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | Takeda Pharmaceutical Company Limited (JP) | 2021-10-27 | — | — | EP | disclosed |
| CN-112438905-B | Moisturizing and skin-brightening composition and application thereof | 澳思美日用化工（广州）有限公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3297678-B1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LTD (IN) | 2021-07-07 | — | — | EP | disclosed |
| US-20210188906-A1 | TUBULYSIN ANALOGUES AS ANTICANCER AGENTS AND PAYLOADS FOR ANTIBODY-DRUG CONJUGATES AND METHODS OF TREATMENT THEREWITH | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-06-24 | — | — | US | disclosed |
| CN-109851635-B | Novel alkylated monophosphine ligand and simple preparation method thereof | 湖北大学 | 2021-03-16 | — | — | CN | disclosed |
| CN-112438905-A | Moisturizing and skin-brightening composition and application thereof | 澳思美日用化工（广州）有限公司 | 2021-03-05 | — | — | CN | disclosed |
| US-10934322-B2 | B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof | ChromaDex Inc. (US) | 2021-03-02 | — | — | US | disclosed |
| CN-112250709-A | Synthesis method of ortho-aryl substituted tertiary phosphine compound | 湖北大学 | 2021-01-22 | — | — | CN | disclosed |
| WO-2020239039-A1 | METHOD FOR PREPARING TETRAZINE COMPOUNDS AND APPLICATION THEREOF | 四川大学华西医院 | 2020-12-03 | — | — | WO | disclosed |
| CN-111592567-A | Synthesis method of bidentate phosphine ene ligand | 湖北大学 | 2020-08-28 | — | — | CN | disclosed |
| WO-2020130152-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-25 | — | — | WO | disclosed |
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2020-02-27 | — | — | US | disclosed |
| WO-2019227527-A1 | FLUORESCENTLY LABELED AMINO ACID, PREPARATION METHOD THEREFOR, AND USE THEREOF | 苏州百源基因技术有限公司 (CN) | 2019-12-05 | — | — | WO | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| CN-105980361-B | For treating the 5- benzylisoquinoline derivative of cardiovascular disease | 法国施维雅药厂 | 2019-05-21 | — | — | CN | disclosed |
| CN-104844687-B | The amino-acid ester prodrug of alkyl amino-substituted dicyan yl pyrimidines and they | 拜耳知识产权有限责任公司 | 2019-04-02 | — | — | CN | disclosed |
| US-20180258127-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | ChromaDex Inc. (US) | 2018-09-13 | — | — | US | disclosed |
| US-10000520-B2 | B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof | ChromaDex Inc. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9963475-B2 | Anthracene-9, 10-dione dioxime compound prodrugs and their uses | BETA CAT PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170334936-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | Iterion Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
| US-20170267709-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OFNICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | ChromaDex Inc. (US) | 2017-09-21 | — | — | US | disclosed |
| CN-106467494-A | Amino-acid ester soluble derivative of laevo-ornidazole and application thereof | 陕西合成药业股份有限公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-106467546-A | Clopidogrel derivant and its production and use | 陕西合成药业股份有限公司 | 2017-03-01 | — | — | CN | disclosed |
| US-9434760-B2 | Prolinamide derivatives as thrombin inhibitors, preparation method and application thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2016-09-06 | — | — | US | disclosed |
| US-9399639-B2 | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use | CALITOR SCIENCES, LLC (US) | 2016-07-26 | — | — | US | disclosed |
| EP-2995615-A1 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2016-03-16 | — | — | EP | disclosed |
| US-9250525-B2 | Resist underlayer film-forming composition | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| CN-105254682-A | Planar chiral ferrocene compound, synthetic method and application | SHANGHAI INST ORGANIC CHEM | 2016-01-20 | — | — | CN | disclosed |
| US-20150362838-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL IND LTD (JP) | 2015-12-17 | — | — | US | disclosed |
| US-9212255-B2 | Resist underlayer film-forming composition | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| EP-2272825-B1 | Protected amino hydroxy adamantane carboxylic acid and process for its preparation | ASTRAZENECA AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| CN-103739591-B | 7-(3-acylamino-4-oxyiminomethyl-1-piperidyl) fluoroquinolone carboxylic acid and preparation method thereof | ZHEJIANG STARRY PHARMACEUTICAL CO LTD | 2015-07-15 | — | — | CN | disclosed |
| US-9073955-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9029567-B2 | Hypoglycemic compounds | CADILA PHARMACEUTICALS LIMITED (IN) | 2015-05-12 | — | — | US | disclosed |
| US-8993523-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20150087155-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-03-26 | — | — | US | disclosed |
| US-8889862-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-11-18 | — | — | US | disclosed |
| CN-103347874-B | dimeric IAP inhibitors | NOVARTIS AG (CH) | 2014-10-29 | — | — | CN | disclosed |
| EP-2292639-B1 | Tubulisine derivatives as anticancer drugs | KEMOTECH S R L (IT) | 2014-09-03 | — | — | EP | disclosed |
| EP-2769978-A1 | saxagliptin derivatives | Cadila Pharmaceuticals Limited (IN) | 2014-08-27 | — | — | EP | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| CN-103739591-A | 7-(3-acylamino-4-oxyiminomethyl-1-piperidyl) fluoroquinolone carboxylic acid and preparation method thereof | ZHEJIANG STARRY PHARMACEUTICAL CO LTD | 2014-04-23 | — | — | CN | disclosed |
| EP-2203443-B1 | PRODRUGS TO THYROID HORMONE ANALOGS | HOFFMANN LA ROCHE (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-20140056849-A1 | SUBSTITUTED AZAINDOLE COMPOUNDS, SALTS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-02-27 | — | — | US | disclosed |
| EP-1559710-B1 | Dipeptidyl peptidase IV inhibitors based on cyclopropyl-fused pyrrolidine, process for their preparation and their use | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| CN-102807601-B | Aminoacyl-tryptophanyl-5-methoxytryptamine and preparation method and application thereof | UNIV CAPITAL MEDICAL SCIENCES | 2014-02-26 | — | — | CN | disclosed |
| US-20140051667-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-02-20 | — | — | US | disclosed |
| US-8653080-B2 | Methods for screening and compounds that protect against amyloid diseases | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2014-02-18 | — | — | US | disclosed |
| US-20140045865-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-02-13 | — | — | US | disclosed |
| US-8592398-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| US-8580820-B2 | Tubulysin compounds with high cytotoxicity, pharmaceutical compositions thereof, and method of use thereof | KEMTECH S.R.L. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-20130296245-A1 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2013-11-07 | — | — | US | disclosed |
| EP-2651917-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| CN-103347874-A | Dimeric iap inhibitors | NOVARTIS AG | 2013-10-09 | — | — | CN | disclosed |
| CN-101652383-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2013-09-18 | — | — | CN | disclosed |
| CN-103261186-A | Dimeric IAP inhibitors | NOVARTIS AG | 2013-08-21 | — | — | CN | disclosed |
| US-20130150578-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | CADILA PHARMACEUTICALS LIMITED (IN) | 2013-06-13 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-RE44186-E1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2555617-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | Cadila Pharmaceuticals Limited (IN) | 2013-02-13 | — | — | EP | disclosed |
| CN-102807601-A | Aminoacyl-tryptophanyl-5-methoxytryptamine and preparation method and application thereof | UNIV CAPITAL MEDICAL | 2012-12-05 | — | — | CN | disclosed |
| CN-101648891-B | Aryl cyclobutyl compound and application thereof in preparing weight-losing medicine | BEIJING JIASHI LIANBO PHARMACEUTICAL TECHNOLOGY CORP | 2012-11-28 | — | — | CN | disclosed |
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-06-21 | — | — | US | disclosed |
| WO-2012080260-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| CN-102464701-A | Novel compound, preparation method and application thereof | SHANGHAI INST PHARM INDUSTRY | 2012-05-23 | — | — | CN | disclosed |
| US-8076334-B2 | Prodrugs of thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| WO-2011125011-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | CADILA PHARMACEUTICALS LIMITED (IN) | 2011-10-13 | — | — | WO | disclosed |
| US-20110200581-A1 | PHARMACEUTICAL COMPOSITIONS | KEMOTECH S.r.I (IT) | 2011-08-18 | — | — | US | disclosed |
| EP-1879895-B1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-06-08 | — | — | EP | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| EP-2292639-A1 | Tubulisine derivatives as anticancer drugs | Kemotech S.r.l. (IT) | 2011-03-09 | — | — | EP | disclosed |
| EP-2272825-A2 | N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | disclosed |
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7842626-B2 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100263062-A1 | METHODS FOR SCREENING AND COMPOUNDS THAT PROTECT AGAINST AMYLOID DISEASES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100263062-A1 | METHODS FOR SCREENING AND COMPOUNDS THAT PROTECT AGAINST AMYLOID DISEASES | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2010-10-14 | — | — | US | disclosed |
| CN-1690066-B | Antiviral agent cidofovir derivatives | HENGDIAN GROUP CHENGDU MOLECULE LAB CO LTD | 2010-04-28 | — | — | CN | disclosed |
| CN-1690067-B | Antiviral agent cyclo-cidofovir derivatives | HENGDIAN GROUP CHENGDU MOLECULE LAB CO LTD | 2010-04-14 | — | — | CN | disclosed |
| CN-101676264-A | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LAB | 2010-03-24 | — | — | CN | disclosed |
| CN-101652383-A | Hepatitis c virus inhibitors | SQUIBB BRISTOL MYERS CO US | 2010-02-17 | — | — | CN | disclosed |
| CN-101648891-A | Aryl cyclobutyl compound and application thereof in preparing weight-losing medicine | BEIJING JIASHI LIANBO PHARMACE | 2010-02-17 | — | — | CN | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-1377288-B1 | 2,1-OXAZOLINE AND 1,2-PYRAZOLINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND USE | BRISTOL MYERS SQUIBB CO (US) | 2009-09-23 | — | — | EP | disclosed |
| CN-100494207-C | Antiviral agent cidofovir derivatives and intermediates thereof | HENGDIAN GROUP CHENGDU MOLECUL (CN) | 2009-06-03 | — | — | CN | disclosed |
| US-20090124680-A1 | USE OF PRODRUG COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR MANUFACTURE OF MEDICAMENT FOR TREATMENT OR PREVENTION OF DISEASES INVOLVING METABOLIC SYNDROME | MAZENCE INC. (KR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124680-A1 | USE OF PRODRUG COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR MANUFACTURE OF MEDICAMENT FOR TREATMENT OR PREVENTION OF DISEASES INVOLVING METABOLIC SYNDROME | MAZENCE INC. (KR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124680-A1 | USE OF PRODRUG COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR MANUFACTURE OF MEDICAMENT FOR TREATMENT OR PREVENTION OF DISEASES INVOLVING METABOLIC SYNDROME | MAZENCE INC. (KR) | 2009-05-14 | — | — | US | disclosed |
| CN-101421291-A | Process for the manufacture of lysobactin derivatives | AICURIS GMBH & CO KG (DE) | 2009-04-29 | — | — | CN | disclosed |
| US-20090082310-A1 | PRODRUGS OF THYROID HORMONE ANALOGS | HAYNES NANCY-ELLEN | 2009-03-26 | — | — | US | disclosed |
| US-7473658-B2 | Partially fluorinated amino acid derivatives as gelling and surface active agents | E. I. DU PONT NEMOURS AND COMPANY (US) | 2009-01-06 | — | — | US | disclosed |
| CN-101274958-A | Bioactive peptide, preparation thereof and application thereof | OCEAN UNIV CHINA (CN) | 2008-10-01 | — | — | CN | disclosed |
| CN-100390169-C | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2008-05-28 | — | — | CN | disclosed |
| EP-1261586-B1 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | BRISTOL MYERS SQUIBB CO (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20080113172-A1 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080113573-A1 | Partially fluorinated amino acid derivatives as gelling and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| CN-100371323-C | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2008-02-27 | — | — | CN | disclosed |
| EP-1879895-A1 | ENZYME INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-0932606-B1 | INHIBITORS OF PRENYL TRANSFERASES | SOD CONSEILS RECH APPLIC (FR) | 2007-12-12 | — | — | EP | disclosed |
| EP-1338588-B1 | METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE | TOKUYAMA CORP (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-7265140-B2 | Acyloxymethylcarbamate prodrugs of oxazolidinones | PFIZER INC (US) | 2007-09-04 | — | — | US | disclosed |
| EP-0711177-B1 | IMPROVEMENTS RELATING TO THE PREPARATION OF PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 2007-05-09 | — | — | EP | disclosed |
| US-7199264-B2 | Method of resolving optical isomers of amino acid derivative | TOKUYAMA CORPORATION (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1668005-B1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN CO LLC (US) | 2007-02-14 | — | — | EP | disclosed |
| CN-1298703-C | Cyanopyrrolidine Derivatives | TAISHO PHARMACENTICAL CO LTD (JP) | 2007-02-07 | — | — | CN | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| CN-1839150-A | Lipopeptide antibacterial derivative composition and application method thereof | MIGENIX INC (CA) | 2006-09-27 | — | — | CN | disclosed |
| CN-1273444-C | Dipeptide nitriles | NOVARTIS AG (CH) | 2006-09-06 | — | — | CN | disclosed |
| EP-1668005-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | Pharmacia & Upjohn Company LLC (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| CN-1772733-A | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-05-17 | — | — | CN | disclosed |
| CN-1753888-A | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2006-03-29 | — | — | CN | disclosed |
| CN-1715269-A | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2006-01-04 | — | — | CN | disclosed |
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | PHARMACIA & UPJOHN COMPANY LLC | 2005-12-01 | — | — | US | disclosed |
| CN-1703399-A | Pharmaceutical compositions as dipeptidyl peptidase-IV (DPP-IV) inhibitors | ABBOTT LAB (US) | 2005-11-30 | — | — | CN | disclosed |
| CN-1698601-A | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use | BRISTOL MYERS SQUIBB CO (US) | 2005-11-23 | — | — | CN | disclosed |
| EP-1559710-A2 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use | Bristol-Myers Squibb Company (US) | 2005-08-03 | — | — | EP | disclosed |
| CN-1213028-C | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, methods for their preparation and uses thereof | BRISTOL MYERS SQUIBB CO (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| CN-1629155-A | Pyrimidinyl carboxylic acid amide compounds with anti-tumor activity and salts thereof | SHANGHAI XINXING MEDICAL CO LT (CN) | 2005-06-22 | — | — | CN | disclosed |
| WO-2005028473-A1 | ACYLOXYMETHYLCARBAMATE PRODRUGS OF OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1377288-A4 | 2,1-OXAZOLINE AND 1,2-PYRAZOLINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
| US-20040102646-A1 | Method of resolving optical isomers of amino acid derivative | TOKUYAMA CORPORATION (JP) | 2004-05-27 | — | — | US | disclosed |
| CN-1474809-A | Cyanopyrrolidine Derivatives | ������ҩ��ʽ���� | 2004-02-11 | — | — | CN | disclosed |
| CN-1473145-A | Method for separating optical isomers of amino acid derivatives | ��ʽ�����ɽ | 2004-02-04 | — | — | CN | disclosed |
| EP-1377288-A1 | 2,1-OXAZOLINE AND 1,2-PYRAZOLINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHOD | Bristol-Myers Squibb Company (US) | 2004-01-07 | — | — | EP | disclosed |
| EP-1338588-A1 | METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE | TOKUYAMA CORPORATION (JP) | 2003-08-27 | — | — | EP | disclosed |
| CN-1427826-A | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, methods for their preparation and uses thereof | BRISTOL MYERS SQUIBB CO (US) | 2003-07-02 | — | — | CN | disclosed |
| US-6573287-B2 | For therapy of diabetes, especially Type II diabetes, as well as impaired glucose homeostasis, impaired glucose tolerance, infertility, polycystic ovary syndrome, growth disorders, frailty, arthritis, allograft rejection in transplantation | BRISTO-MYERS SQUIBB COMPANY | 2003-06-03 | — | — | US | disclosed |
| CN-1405184-A | Anti-small cell lung carcinoma polypeptide mixture | YIKANG BIOCHEMICAL ENGINEERING (CN) | 2003-03-26 | — | — | CN | disclosed |
| CN-1100786-C | Novel aspartyl dipeptide amide derivatives and sweeteners | AJINOMOTO KK (JP) | 2003-02-05 | — | — | CN | disclosed |
| US-6500841-B1 | ADMINISTERING ENZYME/TRANSFERASE INHIBITORS SUCH AS N-(N-(AMINO-3-MERCAPTOPROPYLAMINO)-3-METHYLPENTYL)-1,2,3,4-TETRAHYDRO-3 -ISOQUINOLINECARBOXYL)-METHIONINE METHYL ESTER, AS ANTICARCINOGENIC AGENTS OR PRODRUGS | MERCK & CO., INC. | 2002-12-31 | — | — | US | disclosed |
| US-20020183367-A1 | 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-05 | — | — | US | disclosed |
| EP-1261586-A2 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | Bristol-Myers Squibb Company (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002083128-A1 | 2,1-OXAZOLINE AND 1,2-PYRAZOLINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-24 | — | — | WO | disclosed |
| US-6395767-B2 | ANTIDIABETIC AGENTS; SAXAGLIPTIN | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-28 | — | — | US | disclosed |
| US-20020019411-A1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | US | disclosed |
| WO-2001068603-A2 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL IV, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | BRISTOL-MYERS SQUIBB CO. (US) | 2001-09-20 | — | — | WO | disclosed |
| CN-1278244-A | Dipeptide nitriles | NOVARTIS AG (CH) | 2000-12-27 | — | — | CN | disclosed |
| EP-1028942-A2 | DIPEPTIDE NITRILES | Novartis AG (CH) | 2000-08-23 | — | — | EP | disclosed |
| CN-1261894-A | Polyol-amino-acid compounds having anti-helicobactor pylori activity | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-08-02 | — | — | CN | disclosed |
| EP-0932606-A4 | INHIBITORS OF PRENYL TRANSFERASES | BIOMEASURE INC (US) | 2000-01-19 | — | — | EP | disclosed |
| EP-0932606-A1 | INHIBITORS OF PRENYL TRANSFERASES | Biomeasure Incorporated (US) | 1999-08-04 | — | — | EP | disclosed |
| WO-1999024460-A2 | DIPEPTIDE NITRILES | NOVARTIS AG (CH) | 1999-05-20 | — | — | WO | disclosed |
| CN-1192746-A | Peptide derivatives and angiotensin IV receptor agonists | SAGAMI CHEM RES (JP) | 1998-09-09 | — | — | CN | disclosed |
| US-5773455-A | Inhibitors of prenyl transferases | BIOMEASURE, INCORPORATED (US) | 1998-06-30 | — | — | US | disclosed |
| US-5770731-A | PROTECTING GROUPS, ANTIBODY DIRECTED ENZYME/PRODRUG THERAPY, ANTICARCINOGENIC AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| CN-1174201-A | Novel aspartyl dipeptide amide derivatives and sweeteners | AJINOMOTO KK (JP) | 1998-02-25 | — | — | CN | disclosed |
| WO-1998000409-A1 | INHIBITORS OF PRENYL TRANSFERASES | BIOMEASURE INCORPORATED (US) | 1998-01-08 | — | — | WO | disclosed |
| EP-0755383-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1997-08-27 | — | — | EP | disclosed |
| CN-1145075-A | Antagonist's of endothelin receptors | JAPAT LTD (CH) | 1997-03-12 | — | — | CN | disclosed |
| EP-0755383-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0753004-A1 | ANTAGONISTS OF ENDOTHELIN RECEPTORS | Japat Ltd (CH) | 1997-01-15 | — | — | EP | disclosed |
| US-5536750-A | ANTITUMOR | MERCK & CO., INC. (US) | 1996-07-16 | — | — | US | disclosed |
| EP-0711177-A1 | IMPROVEMENTS RELATING TO PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-15 | — | — | EP | disclosed |
| US-5480893-A | ANTITUMOR | MERCK & CO., INC. (US) | 1996-01-02 | — | — | US | disclosed |
| EP-0668856-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE. | MERCK & CO INC (US) | 1995-11-22 | — | — | EP | disclosed |
| WO-1995026360-A1 | ANTAGONISTS OF ENDOTHELIN RECEPTORS | JAPAT LTD. (CH) | 1995-10-05 | — | — | WO | disclosed |
| WO-1995025092-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-09-21 | — | — | WO | disclosed |
| EP-0668856-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1995-08-30 | — | — | EP | disclosed |
| US-5439918-A | Prodrug for cancer therapy | MERCK & CO., INC. (US) | 1995-08-08 | — | — | US | disclosed |
| EP-0641319-A1 | N- N'-(5-AMINO-4-HYDROXY-ACYLOYL)-$g(a)-AMINOACYLOYL] SUBSTITUTED HETEROCYCLES AND THEIR USE AS ANTIVIRAL AGENTS | Pfizer Limited (GB) | 1995-03-08 | — | — | EP | disclosed |
| WO-1995003830-A2 | PRODRUGS OF FARNESYL TRANSFERASE INHIBITORS FOR ADEPT OR VDEPT | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
| US-5340828-A | Anticarcinogenic agents | MERCK & CO., INC. (US) | 1994-08-23 | — | — | US | disclosed |
| US-5326773-A | Prodrug enzyme inhibitors | MERCK & CO., INC. (US) | 1994-07-05 | — | — | US | disclosed |
| WO-1994010137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1993023373-A1 | N-[N'-(5-AMINO-4-HYDROXY-ACYLOYL)-α-AMINOACYLOYL] SUBSTITUTED HETEROCYCLES AND THEIR USE AS ANTIVIRAL AGENTS | PFIZER LIMITED (GB) | 1993-11-25 | — | — | WO | disclosed |
| EP-0535730-A2 | Inhibitors of farnesyl protein transferase | MERCK & CO. INC. (US) | 1993-04-07 | — | — | EP | disclosed |
| CN-1047870-A | Suppress the peptide class of feritin, their preparation method and their application aspect medical | BAYER AG (DE) | 1990-12-19 | — | — | CN | disclosed |
| US-4510241-A | BASED ON AXCTIVATING A PROCLOTTIN ENZYME FROM AN AMOEBA FROM HORSE | MALLINCKRODT, INC. (US) | 1985-04-09 | — | — | US | disclosed |
| US-4406832-A | Peptide-type substrates useful in the quantitative determination of endotoxin | MALLINCKRODT, INC. (US) | 1983-09-27 | — | — | US | disclosed |
| EP-0074761-A1 | Peptide-type substrates useful in the quantitative determination of endotoxin | WHITTAKER CORPORATION (US) | 1983-03-23 | — | — | EP | disclosed |
| US-RE30752-E | CHEMICAL REACTANT FOR PROTECTING AMINO OR IMINO GROUPS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-29 | — | — | US | disclosed |
| US-4204991-A | Sarcosine1 dehydroalanine8 angiotensin II derivatives | G. D. SEARLE & CO. (US) | 1980-05-27 | — | — | US | disclosed |
| US-4146614-A | TREATMENT OF SCHIZOPHRENIA | STATE OF MICHIGAN (US) | 1979-03-27 | — | — | US | disclosed |
| US-4146614-A | TREATMENT OF SCHIZOPHRENIA | STATE OF MICHIGAN (US) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (36 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113172-A1 | Partially fluorinated compositions and surface active agents | FLNB, FLNA, FSCN1 | CTSS 2311/4885CTSK 1579/4885ALDH1A1 4059/4885 |
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | CTSS 1102/4885CTSK 906/4885ALDH1A1 220/4885 |
| US-20240217930-A1 | SARS-COV-2 MPRO INHIBITOR COMPOUNDS | ACE2, SARS1, ACE | CTSS 576/4885CTSK 1475/4885ALDH1A1 2710/4885 |
| US-20130296245-A1 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF | PREP, TFPI, PEPD | CTSS 280/4885CTSK 265/4885ALDH1A1 1690/4885 |
| US-20040102646-A1 | Method of resolving optical isomers of amino acid derivative | ALAD, AAAS, BCAT1 | CTSS 4304/4885CTSK 4361/4885ALDH1A1 3448/4885 |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | CTSS 1739/4885CTSK 1661/4885ALDH1A1 4204/4885 |
| US-20050267104-A1 | E.g., ({[Acetyl({(5R)-3-[4-(1,1-dioxidotetrahydro-2H-thiopyran4-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl}-methyl)amino]carbonyl}oxymethyl acetate; these compounds have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria | HDAC3, HDAC1, OGA | CTSS 3028/4885CTSK 1988/4885ALDH1A1 591/4885 |
| US-10934322-B2 | B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof | NAMPT, NAPRT, NNT | CTSS 4312/4885CTSK 4289/4885ALDH1A1 2428/4885 |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | CTSS 2004/4885CTSK 1818/4885ALDH1A1 4312/4885 |
| US-10000520-B2 | B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof | NAMPT, NAPRT, NNMT | CTSS 4478/4885CTSK 4555/4885ALDH1A1 2260/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | CTSS 4022/4885CTSK 4661/4885ALDH1A1 2330/4885 |
| US-20020019411-A1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | DPP4, DPP3, DPP7 | CTSS 2165/4885CTSK 1842/4885ALDH1A1 1033/4885 |
| US-20200062730-A1 | NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF | CRBN, PDCD11, CD47 | CTSS 4679/4885CTSK 4676/4885ALDH1A1 613/4885 |
| US-20140056849-A1 | SUBSTITUTED AZAINDOLE COMPOUNDS, SALTS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE | TPMT, CYP3A5, AZI2 | CTSS 988/4885CTSK 1759/4885ALDH1A1 514/4885 |
| US-20210188906-A1 | TUBULYSIN ANALOGUES AS ANTICANCER AGENTS AND PAYLOADS FOR ANTIBODY-DRUG CONJUGATES AND METHODS OF TREATMENT THEREWITH | TEK, CD2BP2, SDCBP | CTSS 1075/4885CTSK 900/4885ALDH1A1 3809/4885 |
| US-11192878-B2 | Piperidine-2,6-dione derivative and use thereof | CRBN, PDCD11, CD47 | CTSS 4679/4885CTSK 4645/4885ALDH1A1 598/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | CTSS 896/4885CTSK 643/4885ALDH1A1 4771/4885 |
| US-12625431-B2 | EUV resist underlayer film-forming composition | EEF1A1, ARF1, EMG1 | CTSS 4528/4885CTSK 3728/4885ALDH1A1 2046/4885 |
| US-20130150578-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | GLP1R, GPR119, IAPP | CTSS 3596/4885CTSK 3616/4885ALDH1A1 818/4885 |
| US-20170334936-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | ACR, TOP2B, TOP2A | CTSS 3709/4885CTSK 1893/4885ALDH1A1 739/4885 |
| US-20110200581-A1 | PHARMACEUTICAL COMPOSITIONS | NR1H3, NR1H2, CCR8 | CTSS 1760/4885CTSK 1351/4885ALDH1A1 4425/4885 |
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | TRPA1, TRPV1, TRPV2 | CTSS 2304/4885CTSK 2270/4885ALDH1A1 914/4885 |
| US-20140045865-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | CTSS 2404/4885CTSK 2087/4885ALDH1A1 694/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | CTSS 608/4885CTSK 1751/4885ALDH1A1 723/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | CTSS 1198/4885CTSK 476/4885ALDH1A1 1343/4885 |
| US-20180258127-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | NAMPT, NAPRT, NNT | CTSS 4312/4885CTSK 4289/4885ALDH1A1 2428/4885 |
| US-20020183367-A1 | 2,1-Oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method | DPP4, DPP7, DPP3 | CTSS 3652/4885CTSK 2472/4885ALDH1A1 546/4885 |
| US-20170267709-A1 | B-VITAMIN AND AMINO ACID CONJUGATES OFNICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF, AND METHODS OF PREPARATION THEREOF | NAMPT, NAPRT, NNMT | CTSS 4478/4885CTSK 4555/4885ALDH1A1 2260/4885 |
| US-20250059171-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, ACE, EIF2AK2 | CTSS 95/4885CTSK 125/4885ALDH1A1 2030/4885 |
| US-20100263062-A1 | METHODS FOR SCREENING AND COMPOUNDS THAT PROTECT AGAINST AMYLOID DISEASES | HTT, IAPP, APP | CTSS 873/4885CTSK 1016/4885ALDH1A1 3311/4885 |
| US-20140051667-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | CTSS 2404/4885CTSK 2087/4885ALDH1A1 694/4885 |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | CTSS 1398/4885CTSK 2435/4885ALDH1A1 333/4885 |
| US-20090082310-A1 | PRODRUGS OF THYROID HORMONE ANALOGS | THRB, THRA, TPO | CTSS 1714/4885CTSK 2835/4885ALDH1A1 727/4885 |
| US-11274124-B2 | Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith | TEK, CD2BP2, SDCBP | CTSS 1075/4885CTSK 900/4885ALDH1A1 3809/4885 |
| US-20090124680-A1 | USE OF PRODRUG COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR MANUFACTURE OF MEDICAMENT FOR TREATMENT OR PREVENTION OF DISEASES INVOLVING METABOLIC SYNDROME | NQO1, CYP27A1, NNMT | CTSS 1249/4885CTSK 1186/4885ALDH1A1 756/4885 |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | CTSZ, CTSF, CTSL | CTSS 7/4885CTSK 8/4885ALDH1A1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.